LeMaitre Vascular Acquires Biologic Patch Business from Admedus
LeMaitre Vascular, Inc. (LMAT)
Last lemaitre vascular, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
lemaitre.gcs-web.com/investor-relations
Company Research
Source: GlobeNewswire
BURLINGTON, Mass., Oct. 13, 2019 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), announced that it has acquired the biologic patch business of Admedus Ltd (ASX: AHZ) for $15.5 million, of which $14.2 million was paid at closing and $1.3 million is due in two post-closing installments, as well as potential earnout payments of $7.8 million payable based upon performance of the acquired business as well as other milestones. The parties also signed a license agreement for the tissue processing technology limited to the CardioCel and VascuCel product lines and a transition services agreement under which Admedus will continue to manufacture the products for up to three years while LeMaitre Vascular transitions manufacturing to its US headquarters. LeMaitre Vascular will not take ownership of the Admedus factory in Perth, Australia. The acquired patches, marketed under the brands CardioCel® and VascuCel®, are processed in a manner that is intended to reduce the risk of calci
Show less
Read more
Impact Snapshot
Event Time:
LMAT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LMAT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LMAT alerts
High impacting LeMaitre Vascular, Inc. news events
Weekly update
A roundup of the hottest topics
LMAT
News
- LeMaitre Vascular, Inc. (NASDAQ: LMAT) was upgraded by analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating. They now have a $75.00 price target on the stock, up previously from $59.00.MarketBeat
- LeMaitre Will Announce First Quarter 2024 Earnings Results May 2, 2024GlobeNewswire
- LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat? [Yahoo! Finance]Yahoo! Finance
- LeMaitre Vascular, Inc. (NASDAQ: LMAT) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- LeMaitre Vascular, Inc. (NASDAQ: LMAT) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
LMAT
Earnings
- 2/27/24 - Beat
LMAT
Sec Filings
- 4/16/24 - Form ARS
- 4/16/24 - Form DEF
- 4/1/24 - Form 4
- LMAT's page on the SEC website